Optimal Shock Energy for Electrical Cardioversion of Atrial Fibrillation
NCT07610980 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400
Last updated 2026-05-28
Summary
Introduction For elective electrical cardioversion of atrial fibrillation, the recommended standard is the administration of a biphasic direct current shock. However, there is considerable variability among physicians regarding the choice of the initial shock energy, as current clinical guidelines do not specify it precisely. The guidelines of American cardiology societies recommend a shock intensity of at least 200 J, while the European Society of Cardiology guidelines do not comment on shock energy at all.
Evidence from a previous randomized clinical trial has shown that using a higher initial shock energy (360 J) is more effective, safe, and reduces the cumulative delivered energy, since lower initial shock energy more frequently requires repeated shocks. The safety of the maximal-energy protocol was demonstrated in this study, among other by the absence of myocardial injury as assessed by cardiac troponin I levels measured 4 hours after electrical cardioversion. However, in this study, the maximal initial shock energy protocol was compared with a low-energy escalating protocol (125-150-200 J), which is no longer supported by current clinical guidelines.
Objective The primary objective of the study is to compare the efficacy (short-term maintenance of sinus rhythm and the need for repeated shocks) of two regimens commonly used in clinical practice: 200-360-360 J and 360-360-360 J.
Secondary objectives are to identify factors that would justify the use of either lower or higher initial shock energy. Another secondary objective is to confirm the safety of the maximal initial shock energy protocol by assessing the biomarker of acute stress (copeptin) in a subpopulation of patients (n = 60).
Methods The main inclusion criterion for the study is the presence of atrial fibrillation or atypical atrial flutter and a clinical indication for electrical cardioversion raised an independent cardiologist. The main exclusion criterion is the presence of typical atrial flutter or focal atrial tachycardia, for which lower shock energy is recommended.
This is a prospective, randomized, single-blind (patient) study in which patients will be randomly assigned in a 1:1:1 ratio either to (i) 200-360-360 J protocol, (ii) 360-360-360 J protocol, or (iii) individualized selection of one of the above protocols based on additional parameters. I one of parameters next parameters is met, the 360-360-360 J protocol will be applied, if not, the 200-360-360 J protocol will be applied: Left atrial size \> 55 mm, duration of the arrhythmia \> 12 months, BMI \> 30 kg/m2, chest circumference \> 120 cm.
Since chest dimensions and the amount of subcutaneous fat may influence resistance to electrical current and thereby reduce the delivered electrical energy, chest dimensions and configuration will be evaluated prior to electrical cardioversion in addition to height and weight. The procedure itself (electrical cardioversion) will then be performed according to the standard institutional clinical practice.
Conditions
- Atrial Fibrillation (AF)
Interventions
- PROCEDURE
-
Direct current biphasic electrical cardioversion
Direct current biphasic electrical cardioversion using Lifepak 20e (Medtronic) external defibrilator will be applied in antero-lateral vector.
- DIAGNOSTIC_TEST
-
blood sampling
6 mL blood samples will be taken from periferal vein before electrical cardiac version and 45 minutes after electrical cardiac version to assess biomarkers of stress and myocardial injury in 60 subjects.
Sponsors & Collaborators
-
Motol and Homolka University Hospital
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-05-18
- Primary Completion
- 2028-12-31
- Completion
- 2029-06-30
More Related Trials
-
Bursa Postgraduate Hospital Department of Cardiology
NCT05231967 ·Status: COMPLETED
-
Control Versus Liberal Cardiac Frequency in Patients in Sepse With Atrial Fibrillation of High Ventricular Response
NCT03715556 ·Status: UNKNOWN ·Phase: PHASE3
-
Prevention of Postop Atrial Fibrillation Through Intraoperative Inducibility of Atrial Fibrillation and Amiodarone Treatment
NCT03868150 ·Status: RECRUITING ·Phase: PHASE4
-
Dual Versus Single Shock for Cardioversion of Atrial Fibrillation
NCT03943693 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery
NCT00953212 ·Status: COMPLETED ·Phase: PHASE3
-
Trial of Electrical Versus Pharmacological Cardioversion for RAFF in the ED
NCT01891058 ·Status: COMPLETED ·Phase: NA
-
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
NCT04571385 ·Status: COMPLETED ·Phase: PHASE2
-
High Sensitivity Troponin T Levels Following DC Cardioversion for Atrial Fibrillation / Atrial Flutter
NCT02268799 ·Status: COMPLETED
-
Intracardiac Echocardiography Guided vs. Electroanatomical Mapping System Guided Slow Pathway Ablation in Patients With Atrioventricular Nodal Reentrant Tachycardia
NCT05907863 ·Status: COMPLETED ·Phase: PHASE4
-
Echocardiographic Predictors of Atrial Fibrillation
NCT05044208 ·Status: RECRUITING
-
Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy
NCT00821353 ·Status: COMPLETED ·Phase: PHASE3
-
Rapid Atrial Fibrillation Treatment Strategy
NCT04092621 ·Status: UNKNOWN ·Phase: PHASE4
-
CArdioversion of Short Duration Atrial Fibrillation
NCT02112318 ·Status: TERMINATED
-
Cardiologist-Administered Midazolam vs. Anaesthesiologist-Assisted Propofol Sedation For Transoesophageal Echocardiography-Guided Cardioversion of Atrial Fibrillation
NCT07571447 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation
NCT01924065 ·Status: COMPLETED ·Phase: PHASE3
-
Heart Rhythm Changes in Patients With Atrial Fibrillation After Cardiopulmonary Bypass: a Retrospective Analysis
NCT06553391 ·Status: COMPLETED
-
Use of Amiodarone in Atrial Fibrillation Associated With Severe Sepsis or Septic Shock
NCT02668432 ·Status: TERMINATED ·Phase: PHASE4
-
Atrial Fibrillation After CABG and PCI
NCT04307225 ·Status: COMPLETED
-
Prophylaxis for Patients at Risk to Eliminate Post-operative Atrial Fibrillation
NCT04392921 ·Status: UNKNOWN ·Phase: NA
-
Characterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation
NCT05377216 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Atrial Electromechanical Interval and Pulse Wave Velocity in the Prediction of Recurrence of Atrial Fibrillation
NCT00818012 ·Status: COMPLETED
-
Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study
NCT01850277 ·Status: UNKNOWN ·Phase: PHASE4
-
Ventricular Tachycardia (VT) Ablation or Escalated Drug Therapy
NCT00905853 ·Status: COMPLETED ·Phase: PHASE4
-
Atrial Fibrillation Prior and Post Elective Cardioversion
NCT05926401 ·Status: RECRUITING
-
Efficacy and Safety of Electrical Versus Pharmacological Cardioversion in Early Atrial Fibrillation
NCT00933634 ·Status: COMPLETED ·Phase: NA